the copper peptide found in your own blood plasma
1973
GHK-Cu wasn't discovered in a skincare lab — a UCSF grad student found it by bathing old human liver cells in young donors' blood plasma and watching them start acting young again.
In 1973, a young researcher named Loren Pickart — then a PhD student in biochemistry at the University of California, San Francisco — ran an experiment that sounds like something out of a vampire novel. He took blood plasma from young donors (roughly 20 to 25 years old) and used it to bathe liver tissue from much older donors (60 to 80). The aged cells perked up, started churning out proteins and behaving like younger tissue again. Something in young blood was carrying a regenerative signal that faded with age — a finding that beat Silicon Valley's whole 'young blood' obsession to the punch by some forty years.
Working with collaborator Carl Thaler, Pickart isolated the active factor from human serum and published it in Nature New Biology under a title modern skincare copy would quietly forget: it noted the molecule both 'prolongs survival of normal liver cells' and 'stimulates growth in neoplastic liver tissue.' Translation: the same thing that revived old cells also fed liver-cancer cells in a dish — a genuinely two-edged result. A companion paper confirmed a lab-made version worked too, ruling out contamination, and by 1977 the structure was pinned down: a three-amino-acid chain of glycine–histidine–lysine (hence GHK) that grabs copper ions fast and hard, forming the complex we now call GHK-Cu.
GHK-Cu turns out to be a natural part of human plasma, saliva, and urine — and by Pickart's own published measurements, its levels slump with age, from around 200 ng/mL at 20 to about 80 ng/mL by 60. That decline became the pitch for an anti-aging angle, and Pickart chased it commercially for the rest of his life: he founded ProCyte in 1985 (maker of an FDA-cleared wound gel called Iamin), then Skin Biology in 1994. The real bridge to your bathroom cabinet came in 2000, when ProCyte licensed the molecule to Johnson & Johnson's Neutrogena for firming creams — that deal, not any marketing by Pickart himself, is how a 1970s liver-cancer footnote became a drugstore cosmetic.
Pickart died in December 2023 at age 85, having spent essentially five decades following one small molecule from a petri dish of liver cells all the way to the cosmetics aisle. It's a rare arc in science: one person, one discovery, bench to shelf, for a whole career.
The wild origin story checks out — old liver cells really did perk up in young plasma, the molecule really did double as a cancer-cell stimulant, and the ProCyte-to-Neutrogena path is well documented. Two details got dressed up, though: in 1973 Pickart was a UCSF PhD student, not yet the established biochemist he's often called, and 2026's FDA change removed injectable GHK-Cu from a restricted list pending review — not a full approval.
Today GHK-Cu lives a double life. In one lane it's a totally mainstream, unregulated cosmetic ingredient — listed as <b>copper tripeptide-1</b> — that's been in ordinary anti-aging creams and serums since the Neutrogena deal around 2000, with no FDA approval required or ever granted. In the other, injectable GHK-Cu has become a fixture of the research-peptide and med-spa world; a 2026 FDA shift removed it from the Category 2 'restricted-risk' list, so it's now eligible for prescription compounding at licensed 503A pharmacies — though this is pending further FDA (PCAC) review expected before February 2027, not a full approval or final green light. As for the science: the mechanistic and animal/cell-culture evidence for wound healing, collagen stimulation, and antioxidant and anti-inflammatory effects is genuinely large and decades-deep, but solid large-scale human-trial data for the flashier claims — hair regrowth, whole-body anti-aging, brain protection — is still comparatively thin.
